

NANEXA Equity Research Case Video Summary

See our Equity Research Video Summary of NANEXA covering

- benefits of proprietary drug formulation PharmaShell
- the new project NEX-22
- platform technology licensing and internal drug development pipeline
- timetable
- our rNPV for development projects and platform
- key milestones for the coming year

See Equity Research Case Video Summary here <https://youtu.be/84hwEXta6nM>

For our complete research on NANEXA see https://www.emergers.se/bolag_nanexa/

Contact

Johan Widmark

johan@emergers.se

About Emergers

This is a press release from Emergers.

DISCLAIMER

Information provided here or on Emergers' website [emergers.se](https://www.emergers.se) is not intended to be financial advice. Emergers receives compensation for writing about the company in question. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers' own. Articles of analysis shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot guarantee that the conclusions presented in the analysis will be met. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

For more information and complete terms, please see [emergers.se](https://www.emergers.se).

Attachments

[NANEXA Equity Research Case Video Summary](#)